-
World Hepatitis Day 2025 | Prof. George Lau: Exploring Optimal Strategies for HBV Antiviral Therapy from an Economic Perspective
At the 2025 World Hepatitis Day Campaign Conference and the 7th Academic Conference on Clinical Cure of Chronic Hepatitis B, hosted by the China Foundation for Hepatitis Prevention and Control, Professor George Lau, Chairman of Hong Kong’s Humanity Medical Group and Chief Physician at Zhongshan Hospital affiliated with Fudan University, shared insights on the most…
-
APASL 2025 Expert Interview | Prof. George Lau: Dilemmas and Breakthroughs in Clinical Cure of Chronic Hepatitis B and Liver Cancer Prevention
At the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL 2025), Professor George Lau, Chairman of Hong Kong Humanity Medical Group and Director of Humanity Medical Clinical Research Center, shared important insights on cuttingedge topics including clinical cure of chronic hepatitis B (CHB) and liver cancer prevention. With…
-
China-Led International Real-World Study: TACE Plus Immunotherapy Boosts Survival Beyond 26 Months in Unresectable HCC
The study not only fills a gap in international guidelines regarding treatment strategies for advanced HCC, but also injects fresh insight into global HCC management through a “China‑led approach,”marking China’s…
-
ILCA Roundtable | MDT: Optimizing HCC Treatment Strategies – Insights from the TALENT Series Studies
In recent years, advances in systemic therapy have offered hope for advanced liver cancer patients, but traditional single treatments remain limited, highlighting the need for new approaches. Combining systemic therapy with local treatments has become a key trend, with multidisciplinary team (MDT) collaboration now a global standard. Experts from surgery, interventional radiology, oncology, and more…
-
Prof. Qiang Wei: Gathering Global Expertise to Shape a New Landscape in Uro-Oncology at the West China Tianfu Academic Conference
Editor’s Note: The 9th West China Uro-Oncology Tianfu Academic Conference and the 11th Annual Meeting of the Sichuan Anti-Cancer Association Genitourinary Tumor Committee was successfully held in Chengdu from November…
-
Prof. Hao Zeng: Key Takeaways from the West China Uro-Oncology Tianfu Conference and Advances in Precision Prostate Cancer Management
Editor’s Note: From November 10–16, 2025, the 9th West China Uro-Oncology Tianfu Academic Conference and the 11th Annual Meeting of the Genitourinary Tumor Committee of the Sichuan Anti-Cancer Association were…
-
Prof. Pei Dong: From “Effective” to “Precise” — Current Status and Future Directions of Immunotherapy in Renal Cell Carcinoma
With the rapid progress of clinical research, immunotherapy has demonstrated substantial value across multiple treatment settings in renal cell carcinoma (RCC). In particular, immune-based combination regimens have reshaped the treatment landscape of advanced RCC. At the 9th West China Uro-Oncology Tianfu Academic Conference & the 11th Annual Meeting of the Sichuan Anti-Cancer Association Genitourinary Tumor Committee, Professor Pei Dong from Sun Yat-sen University…
-
West China UroOncology Tianfu Conference丨Professor Wei Xue Shares the Renji Experience in Comprehensive Prostate Cancer Management
01 Oncology Frontier – Urology Frontier: Your team was the first internationally to propose Raman spectroscopy–based noninvasive diagnosis using prostatic fluid. How do these innovations reshape the traditional diagnostic pathway…
Connecting Medical Expertise through Media